EARLY study: Early basal insulin therapy under real-life conditions in type 2 diabetics

Diabetes, Stoffwechsel und Herz

Volumn 21, Issue 2, 2012, Pages 91-97

  Hanefeld, M ^a   Fleischmann, H ^b   Landgraf, W ^b   Pistrosch, F ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c Medical Affairs ^*  (Germany)

Author keywords

Clinical conditions; Early study; Insulin glargine; Metformin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RECOMBINANT HUMAN INSULIN; SOLOSTAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGED; ARTICLE; BLURRED VISION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LEG ULCER; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84860761633     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Deutsche Diabetes-Gesellschaft: Leitlinien. http://www.deutsche-diabetes- gesellschaft.de/redaktion/mitteilungen/leitlinien/leitlinien.php (Zugriff: 24.11.2011)
2. Ryden L, Standi E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D: Guidelines on Diabetes, pre-Diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136. http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/ guidelines-diabetes-ES.pdf (Pubitemid 46137814)
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-853
4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443 (Pubitemid 44903747)
5. Ott P, Benke I, Stelzer J, Kohler C, Hanefeld M: "Diabetes in Germany" (DIG)-Studie. Prospektive 4-Jahres-Studie zur Therapiequalitat bei Typ-2-Diabetes in der Praxis. Dtsch Med Wochenschr 2009; 134: 291-297
6. Del Prato S: Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-1192
7. Defronzo RA, Davidson JA, Del Prato S: The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14: 5-14
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
9. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH, Byington RP, Rosenberg YD, Friedewald WT: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828
10. Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H: Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med 2010; 27: 175-180
11. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765-1772
12. Schulze J, Scholz GH, Verlohren HJ, Hanefeld M, Blüher M, Julius U, Bergmann S, Fischer S, Krug J, Weck M, Pawlick I, Kapellen T, Rothe U et al.; Fachkommission Diabetes SLÄK (Hrsg.): Praxis-Leitlinien Diabetes mellitus Typ 2. Institut für Medizinische Informatik und Biometrie der TU Dresden, 2010
13. Huppertz E, Pieper L, Klotsche J, Stridde E, Pittrow D, Bohler S, Lehnert H: Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes 2009; 117: 6-14
14. Fachinformation Lantus® Solostar®. September 2008
15. Fachinformation Insuman*basal. Juni 2008
16. Riddle M: Counterpoint: Intensive glucose control and mortality in ACCORD - still looking for clues. Diabetes Care 2010; 33: 2722-2724
17. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER: Epidemiologic relationships between AlC and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-990
18. Boyko EJ: ACCORD glycemia results continue to puzzle. Diabetes Care 2010; 33: 1149-1150
19. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007; 6: 13
20. Gleason CE, Gonzalez M, Harmon JS, Robertson RP: Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab 2000; 279: E997-E1002
21. Meneghini L: Early insulin treatment in type 2 diabetes: what are the pros? Diabetes Care 2009; 32 (Suppl 2): S266-S269
22. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371(9626): 1753-1760 (Pubitemid 351697950)
23. Chon S, Oh S, Kim SW, Kim JW, Kim YS, Woo JT: The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med 2010; 25: 273-281
24. Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ: Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011; 34: 2048-2053
25. Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121 (Pubitemid 15102179)
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
27. Fonseca V, Gill J, Zhou R, Leahy J: An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13: 814-822
28. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730 (Pubitemid 350005153)
29. Riddle MC, Rosenstock J, Gerich J: The treatto-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086 (Pubitemid 37339502)
30. Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H: Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med 2010; 27: 175-180